Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 20/20 | 0.56 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.53 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15192368 | 0.88 | MAP3K14 (0.63) | MAP3K14 | |
| SCHEMBL15192690 | 0.87 | MAP3K14 (0.59) | MAP3K14PIK3CDPIK3R1 | |
| SCHEMBL1484994 | 0.81 | MAP3K14 (0.55) | MAP3K14PIK3CDPIK3R1 | |
| SCHEMBL12539137 | 0.81 | MAP3K14 (0.63) | MAP3K14PIK3CDPIK3R1 | |
| SCHEMBL1485171 | 0.81 | MAP3K14 (0.57) | MAP3K14PIK3CDPIK3R1 | |
| SCHEMBL1485001 | 0.81 | MAP3K14 (0.54) | MAP3K14PIK3CDPIK3R1 | |
| SCHEMBL15201726 | 0.79 | MAP3K14 (0.53) | MAP3K14 | |
| SCHEMBL15192886 | 0.79 | MAP3K14 (0.82) | MAP3K14PIK3CDPIK3R1 | |
| SCHEMBL12693227 | 0.78 | MAP3K14 (0.59) | MAP3K14PIK3CDPIK3R1 | |
| SCHEMBL1485427 | 0.78 | MAP3K14 (0.64) | MAP3K14PIK3CDPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150166569-A1 | TRICYCLIC COMPOUNDS AND METHODS OF USE THEREFOR | GENENTECH, INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-9034866-B2 | Tricyclic compounds and methods of use therefor | GENENTECH, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| EP-2814830-A1 | TRICYCLIC COMPOUNDS AND METHODS OF USE THEREFOR | F.HOFFMANN-LA ROCHE AG (CH) | 2014-12-24 | — | — | EP | disclosed |
| WO-2013120980-A1 | TRICYCLIC COMPOUNDS AND METHODS OF USE THEREFOR | F. HOFFMANN-LA ROCHE AG (CH) | 2013-08-22 | — | — | WO | disclosed |
| US-20130217666-A1 | TRICYCLIC COMPOUNDS AND METHODS OF USE THEREFOR | GENENTECH, INC. (US) | 2013-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166569-A1 | TRICYCLIC COMPOUNDS AND METHODS OF USE THEREFOR | NFKB1, NFKBIA, RELA | MAP3K14 1050/4885PIK3CD 1800/4885PIK3R1 730/4885 |
| US-20130217666-A1 | TRICYCLIC COMPOUNDS AND METHODS OF USE THEREFOR | NFKB1, NFKBIA, RELA | MAP3K14 1050/4885PIK3CD 1800/4885PIK3R1 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.